Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by RealPharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RealPharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

340B or Bust: Is This Program Failing the Sick

54:38
 
Share
 

Manage episode 494377311 series 3535889
Content provided by RealPharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RealPharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Absolutely! Here are polished, professional show notes for your episode titled:

🎙️ 340B or Bust: Is This Program Failing the Sick?

This week on Real Pharma, hosts Dr. Na-Ri Oh and Ian Wendt dive into the tangled world of 340B with returning guest William “Bill” Sarraille—one of the most respected voices in healthcare law, an active patient advocate, and a rare disease patient himself.

The 340B Drug Pricing Program was intended to help vulnerable patients by requiring drug manufacturers to provide discounted medications to covered entities. But as Bill puts it, has the program strayed too far from its patient-first mission? With explosive growth, patchwork state laws, opaque data, and billions on the line, is it still doing what it was designed to do—or are the sick paying the ultimate price?

🔍 In this episode, we explore:

✅ How 340B ballooned from a modest program to a behemoth that may soon outpace Medicare Part D
✅ Why transparency remains elusive—and who’s resisting it
✅ The uncomfortable reality: charity care rates at major hospitals vs. billions in 340B profits
✅ The looming risks to rare disease innovation and patient access
✅ Bill’s insider perspective on why patients often aren’t seeing the savings
✅ What changes might be coming from state houses, courts, and possibly Washington

Bill also shares candid insights from his own journey as a rare disease patient—and why that makes him both more hopeful and more skeptical than ever.

💡 Links & Resources Mentioned

  continue reading

39 episodes

Artwork
iconShare
 
Manage episode 494377311 series 3535889
Content provided by RealPharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RealPharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Absolutely! Here are polished, professional show notes for your episode titled:

🎙️ 340B or Bust: Is This Program Failing the Sick?

This week on Real Pharma, hosts Dr. Na-Ri Oh and Ian Wendt dive into the tangled world of 340B with returning guest William “Bill” Sarraille—one of the most respected voices in healthcare law, an active patient advocate, and a rare disease patient himself.

The 340B Drug Pricing Program was intended to help vulnerable patients by requiring drug manufacturers to provide discounted medications to covered entities. But as Bill puts it, has the program strayed too far from its patient-first mission? With explosive growth, patchwork state laws, opaque data, and billions on the line, is it still doing what it was designed to do—or are the sick paying the ultimate price?

🔍 In this episode, we explore:

✅ How 340B ballooned from a modest program to a behemoth that may soon outpace Medicare Part D
✅ Why transparency remains elusive—and who’s resisting it
✅ The uncomfortable reality: charity care rates at major hospitals vs. billions in 340B profits
✅ The looming risks to rare disease innovation and patient access
✅ Bill’s insider perspective on why patients often aren’t seeing the savings
✅ What changes might be coming from state houses, courts, and possibly Washington

Bill also shares candid insights from his own journey as a rare disease patient—and why that makes him both more hopeful and more skeptical than ever.

💡 Links & Resources Mentioned

  continue reading

39 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play